Cardiome Pharma Corp
Oral RSD1235 patient dosing initiated in phase I study
Published in Cardiovascular Business Week, October 26th, 2004
The study is an open-label, cross-over evaluation of two controlled release formulations of RSD1235 in comparison to an immediate release formulation. The study will enable Cardiome to evaluate and select which formulation to move forward into further clinical trials.
A controlled release oral formulation of RSD1235 is being developed as a chronic treatment for atrial fibrillation (AF). Oral RSD1235 is expected to prevent or slow the recurrence of AF, and is designed to be used as a follow-on therapy...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
More Articles from Cardiovascular Business Week
- CardioDynamics
Device firm reports 25th quarter of revenue growth - CardioVascular BioTherapeutics, Inc.
Biopharmaceutical firm files registration statement for IPO - Diomed Holdings, Inc.
EVLT maker agrees to $10.6M financing - Lifestream Technologies, Inc.
Cholesterol monitor developer announces 169% increase in July shipments - Morton Grove Pharmaceuticals
FDA clears Cyclosporine Oral Solution, USP, 100 mg/ml for marketing - Nanobac Life Science, Inc.
Life sciences company completes financing - More from this issue of Cardiovascular Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
